Oxaliplatin
Information
- Drug Name
- Oxaliplatin
- Description
- Entry(CIViC)
- 12
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| 329 consecutive patients with stage II–III colorec... | HSPH1 |
HSPH1 T17 DELETION ( ENST00000320027.10 ) HSPH1 T17 DELETION ( ENST00000320027.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The methylation status of MLH1 was analyzed in a s... | MLH1 | MLH1 METHYLATION MLH1 METHYLATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Of 100 metastatic colorectal cancer patients treat... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Patients with BRCA1/2 associated pancreatic adenoc... | BRCA1 | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| This was a retrospective clinical study of 100 met... | KRAS | KRAS G12/G13 KRAS G12/G13 | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective clinical study of 100 met... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective clinical study of 100 met... | BRAF | BRAF MUTATION BRAF MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Of 100 metastatic colorectal cancer patients treat... | BRAF | BRAF D594K BRAF D594K | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Nuclear expression of DICKKOPF-1 was identified in... | DKK1 | DKK1 NUCLEAR EXPRESSION DKK1 NUCLEAR EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective biomarker analysis of the EX... | TP53 | TP53 WILD TYPE TP53 WILD TYPE | Sensitivity | true | CIViC Evidence | detail |
| 141 patients were analyzed for ERBB2 (HER2) positi... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| OCT4B1 (POU5F1 splice variant) expression reduced ... | POU5F1 | POU5F1 EXPRESSION POU5F1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00680901 | Active, not recruiting | Phase 3 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | June 4, 2008 | January 22, 2025 |
| NCT04908813 | Active, not recruiting | Phase 2 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | September 29, 2021 | December 2025 |
| NCT04513951 | Active, not recruiting | Phase 2 | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | April 1, 2020 | July 31, 2024 |
| NCT04662710 | Active, not recruiting | Phase 3 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) | December 30, 2020 | February 2, 2026 |
| NCT04481204 | Active, not recruiting | Phase 2 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | April 18, 2023 | April 6, 2025 |
| NCT04083235 | Active, not recruiting | Phase 3 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | February 11, 2020 | December 31, 2024 |
| NCT04250948 | Active, not recruiting | Phase 2 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | October 12, 2019 | October 5, 2024 |
| NCT03399110 | Active, not recruiting | Phase 3 | XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) | December 1, 2017 | August 1, 2026 |
| NCT04210115 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | February 28, 2020 | February 1, 2027 |
| NCT04068103 | Active, not recruiting | Phase 2/Phase 3 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | December 16, 2019 | April 30, 2027 |
| NCT03366272 | Active, not recruiting | Phase 2/Phase 3 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients | December 5, 2017 | November 2024 |
| NCT04447092 | Active, not recruiting | Phase 2 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | July 1, 2020 | December 31, 2025 |
| NCT05435313 | Active, not recruiting | Phase 2 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | July 12, 2022 | February 2024 |
| NCT03329248 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | November 6, 2017 | December 2020 |
| NCT00217737 | Active, not recruiting | Phase 3 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | September 6, 2005 | September 30, 2024 |
| NCT03321643 | Active, not recruiting | Phase 1 | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma | September 18, 2018 | June 30, 2025 |
| NCT00104676 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | November 26, 2003 | December 2024 |
| NCT04062656 | Active, not recruiting | Phase 2 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG | September 26, 2019 | June 1, 2025 |
| NCT03281369 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | October 13, 2017 | April 30, 2025 |
| NCT04047862 | Active, not recruiting | Phase 1 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | August 26, 2019 | August 2024 |
| NCT04375605 | Active, not recruiting | Phase 3 | Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ | June 3, 2020 | December 2025 |
| NCT04043195 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | August 14, 2019 | December 2025 |
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT04882241 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | July 29, 2020 | June 27, 2025 |
| NCT03255434 | Active, not recruiting | Phase 2 | LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy | November 1, 2017 | December 2024 |
| NCT04363801 | Active, not recruiting | Phase 2 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | July 29, 2020 | December 2025 |
| NCT03221426 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | October 9, 2017 | June 27, 2025 |
| NCT04304209 | Active, not recruiting | Phase 2 | Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | October 28, 2019 | October 18, 2026 |
| NCT03193190 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | July 5, 2017 | October 31, 2026 |
| NCT04301557 | Active, not recruiting | Phase 2 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | July 31, 2020 | December 30, 2024 |
| NCT03172416 | Active, not recruiting | Phase 1 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis | April 12, 2017 | December 31, 2024 |
| NCT04034459 | Active, not recruiting | Phase 2 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | November 25, 2016 | December 31, 2023 |
| NCT03153280 | Active, not recruiting | Phase 1 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | January 13, 2022 | December 2026 |
| NCT03970252 | Active, not recruiting | Early Phase 1 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | July 24, 2019 | April 2026 |
| NCT03929666 | Active, not recruiting | Phase 2 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | August 29, 2019 | October 30, 2026 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT03852251 | Active, not recruiting | Phase 1/Phase 2 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | January 18, 2019 | August 31, 2023 |
| NCT03783442 | Active, not recruiting | Phase 3 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | December 11, 2018 | June 30, 2024 |
| NCT04182204 | Active, not recruiting | Phase 3 | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | February 7, 2020 | March 30, 2025 |
| NCT05568095 | Active, not recruiting | Phase 3 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | November 21, 2022 | May 2026 |
| NCT03006432 | Active, not recruiting | Phase 3 | PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA | December 19, 2016 | March 2024 |
| NCT04854668 | Active, not recruiting | Phase 3 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | July 30, 2020 | December 31, 2025 |
| NCT05251948 | Active, not recruiting | Phase 1/Phase 2 | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | March 1, 2022 | June 22, 2025 |
| NCT04661150 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | March 12, 2021 | August 30, 2026 |
| NCT00059930 | Active, not recruiting | Phase 1 | Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer | January 2003 | June 2024 |
| NCT02931890 | Active, not recruiting | Phase 2 | Multicentric Randomised Trial for Resectable Gastric Cancer | December 21, 2017 | March 2029 |
| NCT04169347 | Active, not recruiting | Phase 2 | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | December 2, 2019 | January 2025 |
| NCT03777657 | Active, not recruiting | Phase 3 | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | December 13, 2018 | December 31, 2024 |
| NCT05144854 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | November 5, 2021 | May 2027 |
| NCT02912559 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | October 16, 2017 | April 2, 2025 |
| NCT02872116 | Active, not recruiting | Phase 3 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | October 12, 2016 | May 31, 2024 |
| NCT03776487 | Active, not recruiting | Phase 2 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | January 7, 2019 | December 30, 2026 |
| NCT03773367 | Active, not recruiting | Phase 2 | Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | December 14, 2018 | May 31, 2026 |
| NCT03699319 | Active, not recruiting | Phase 1/Phase 2 | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | December 7, 2018 | September 23, 2024 |
| NCT03693807 | Active, not recruiting | Phase 2 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | October 18, 2018 | September 2024 |
| NCT02578368 | Active, not recruiting | Phase 3 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2016 | February 2026 |
| NCT03675737 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | November 8, 2018 | March 1, 2025 |
| NCT03653507 | Active, not recruiting | Phase 3 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | November 28, 2018 | March 31, 2025 |
| NCT02509286 | Active, not recruiting | Phase 3 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus | January 2016 | December 31, 2024 |
| NCT03615326 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | October 5, 2018 | December 30, 2024 |
| NCT04940546 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | June 16, 2021 | October 30, 2024 |
| NCT03406299 | Active, not recruiting | Phase 2 | Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer | April 19, 2018 | December 31, 2023 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT04937738 | Active, not recruiting | Phase 2 | Perioperative Chemotherapy in Gastric Cancer | July 21, 2021 | July 1, 2029 |
| NCT04294264 | Active, not recruiting | Phase 2 | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer | February 12, 2019 | March 31, 2024 |
| NCT00492999 | Active, not recruiting | Phase 2 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | May 2007 | May 2025 |
| NCT02338518 | Active, not recruiting | Phase 3 | Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients | January 4, 2015 | October 2023 |
| NCT04164069 | Active, not recruiting | Phase 1 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | September 2, 2020 | December 31, 2023 |
| NCT04522336 | Active, not recruiting | Phase 1 | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | September 16, 2020 | July 18, 2024 |
| NCT03586869 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | July 28, 2018 | December 2019 |
| NCT04276493 | Active, not recruiting | Phase 1/Phase 2 | Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab | March 26, 2020 | December 31, 2026 |
| NCT02288195 | Active, not recruiting | Phase 3 | CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients | August 13, 2014 | March 2024 |
| NCT02047474 | Active, not recruiting | Phase 2 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | March 25, 2014 | December 2026 |
| NCT02037048 | Active, not recruiting | Phase 2 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | February 10, 2014 | October 1, 2025 |
| NCT04761614 | Active, not recruiting | Phase 1 | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | April 2, 2021 | December 31, 2024 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT04097028 | Active, not recruiting | Phase 2 | Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 20, 2019 | December 16, 2024 |
| NCT04094688 | Active, not recruiting | Phase 3 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | September 30, 2019 | July 2025 |
| NCT04515615 | Active, not recruiting | Phase 2 | Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | September 9, 2020 | September 2025 |
| NCT03533582 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | May 24, 2018 | June 30, 2026 |
| NCT05253846 | Active, not recruiting | Phase 2 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | January 25, 2022 | October 30, 2028 |
| NCT03504397 | Active, not recruiting | Phase 3 | A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer | June 21, 2018 | March 31, 2025 |
| NCT03493048 | Active, not recruiting | Phase 2 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | April 15, 2018 | June 2025 |
| NCT01918527 | Active, not recruiting | Phase 3 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | September 2013 | February 2025 |
| NCT01871571 | Active, not recruiting | Phase 2 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | August 2, 2013 | June 24, 2023 |
| NCT01862315 | Active, not recruiting | Phase 2 | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | May 2013 | May 2025 |
| NCT01191697 | Active, not recruiting | Phase 2 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | February 2011 | July 2024 |
| NCT01081262 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | October 12, 2010 | March 1, 2025 |
| NCT03487016 | Active, not recruiting | Phase 2 | First-line Therapy in Metastatic PDAC | February 15, 2019 | July 2023 |
| NCT00873275 | Active, not recruiting | Phase 1 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 11, 2009 | January 13, 2025 |
| NCT04251715 | Active, not recruiting | Phase 2 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | April 28, 2021 | November 30, 2024 |
| NCT05216653 | Active, not recruiting | Phase 2 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM) | April 7, 2022 | March 31, 2025 |
| NCT03451370 | Active, not recruiting | First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer | November 1, 2017 | December 2024 | |
| NCT00335816 | Active, not recruiting | Phase 2 | Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | August 2008 | December 2024 |
| NCT02436044 | Approved for marketing | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | |||
| NCT00126256 | Completed | Phase 3 | Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer | February 2002 | February 2006 |
| NCT00138177 | Completed | Phase 1 | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors | July 2005 | |
| NCT00142467 | Completed | Phase 2 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | April 2004 | June 2011 |
| NCT00142480 | Completed | Phase 2 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | December 2004 | April 2011 |
| NCT00154791 | Completed | Phase 1/Phase 2 | Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma | March 2003 | August 2005 |
| NCT00159432 | Completed | Phase 2 | Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer | February 2005 | March 2013 |
| NCT00174564 | Completed | Phase 2 | EXIBIT: Oxaliplatin in Biliary Tract Cancer | April 2003 | September 2006 |
| NCT00177307 | Completed | Phase 2 | Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer | January 2005 | February 2012 |
| NCT00186277 | Completed | Phase 2 | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer | December 2003 | December 2006 |
| NCT00191568 | Completed | Phase 2 | Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer | October 2002 | May 2007 |
| NCT00192075 | Completed | Phase 2 | A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer | June 2003 | November 2007 |
| NCT00192088 | Completed | Phase 2 | A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma | May 2004 | May 2006 |
| NCT00193128 | Completed | Phase 1/Phase 2 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | April 2004 | January 2009 |
| NCT00193219 | Completed | Phase 2 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | July 2005 | July 2010 |
| NCT00193609 | Completed | Phase 2 | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | September 2004 | January 2009 |
| NCT00199797 | Completed | Phase 1 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | April 18, 2005 | April 1, 2016 |
| NCT00215982 | Completed | Phase 2 | Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer | December 2004 | July 2007 |
| NCT00216021 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | March 2004 | June 2007 |
| NCT00217581 | Completed | Phase 2 | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer | October 2004 | January 2013 |
| NCT00217711 | Completed | Phase 1/Phase 2 | Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | May 2005 | October 2011 |
| NCT00222469 | Completed | Phase 2 | Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | August 2005 | May 2007 |
| NCT00227747 | Completed | Phase 3 | Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer | November 8, 2005 | July 15, 2013 |
| NCT00242190 | Completed | Phase 1/Phase 2 | Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer | June 2004 | February 2010 |
| NCT00250029 | Completed | N/A | Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen | April 2004 | March 2006 |
| NCT00252564 | Completed | Phase 3 | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | September 2005 | June 2009 |
| NCT00254137 | Completed | Phase 2 | Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | September 2004 | November 2006 |
| NCT00260611 | Completed | Phase 2 | Study of Oxaliplatin and Taxotere in Prostate Cancer | November 2004 | September 2007 |
| NCT00261092 | Completed | Phase 2 | GEMOX: Oxaliplatin in Pancreatic Cancer | October 2005 | |
| NCT00262808 | Completed | Phase 2 | GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer | March 2004 | September 2006 |
| NCT00263029 | Completed | Phase 2 | Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer | June 2002 | |
| NCT00263055 | Completed | Phase 4 | MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV | August 2004 | |
| NCT00263354 | Completed | Phase 2 | Oxaliplatin in Gastric Cancer | October 2003 | July 2006 |
| NCT00266097 | Completed | Phase 1 | Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | August 2004 | September 2011 |
| NCT00268333 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | August 2005 | |
| NCT00278694 | Completed | Phase 2 | Oxaliplatin and 5-FU Based Preoperative Chemoradiation | September 2005 | February 2016 |
| NCT00278889 | Completed | Phase 2 | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | January 2006 | October 2009 |
| NCT00280618 | Completed | Phase 2 | Oxaliplatin in Unresectable Hepatocellular Carcinoma | July 2004 | |
| NCT00281944 | Completed | Phase 1 | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors | September 2005 | |
| NCT00290615 | Completed | Phase 2 | Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | January 2006 | January 2011 |
| NCT00297141 | Completed | Phase 2 | Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma | October 2004 | December 2013 |
| NCT00297596 | Completed | Phase 2 | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | February 2006 | October 2010 |
| NCT00304135 | Completed | Phase 2/Phase 3 | Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery | October 2005 | December 2012 |
| NCT00305188 | Completed | Phase 3 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | December 2005 | October 2009 |
| NCT00305786 | Completed | Phase 2 | Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | August 2005 | May 2010 |
| NCT00308516 | Completed | Phase 2 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | March 2006 | February 2012 |
| NCT00321685 | Completed | Phase 2 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | July 25, 2006 | February 11, 2019 |
| NCT00321828 | Completed | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery | March 2006 | December 2012 |
| NCT00336583 | Completed | Phase 2 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL) | June 2006 | January 2008 |
| NCT00338039 | Completed | Phase 2 | Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | September 2005 | June 2011 |
| NCT00338988 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma | August 2003 | May 2009 |
| NCT00343408 | Completed | Phase 1 | AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer | November 29, 2005 | September 22, 2008 |
| NCT00345761 | Completed | Phase 1/Phase 2 | Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer | February 2006 | July 2010 |
| NCT00350961 | Completed | Phase 1/Phase 2 | Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma | June 2004 | February 2008 |
| NCT00353145 | Completed | Phase 2 | Gemox as First and Second Line Therapy in Unknown Primary Cancer | February 2004 | January 2010 |
| NCT00353262 | Completed | Phase 1 | A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer. | July 2005 | April 2008 |
| NCT00354887 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater | November 2004 | November 2009 |
| NCT00356122 | Completed | Phase 2 | Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | July 2006 | August 2010 |
| NCT00361231 | Completed | Phase 2 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | May 2006 | August 2012 |
| NCT00374660 | Completed | Phase 1/Phase 2 | Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors | June 2003 | April 2007 |
| NCT00381862 | Completed | Phase 2 | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | June 2006 | July 2008 |
| NCT00398320 | Completed | Phase 2 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | November 2006 | October 2012 |
| NCT00399750 | Completed | Phase 2 | TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer | November 2002 | June 2005 |
| NCT00403624 | Completed | Phase 1/Phase 2 | Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer | July 2001 | November 2005 |
| NCT00406302 | Completed | Phase 2 | Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) | January 2007 | June 2011 |
| NCT00408564 | Completed | Phase 2 | Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | January 2006 | April 2013 |
| NCT00411229 | Completed | Phase 3 | Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer | June 2006 | November 2012 |
| NCT00416494 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer | September 2003 | August 2014 |
| NCT00422864 | Completed | Phase 2 | A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer | October 2006 | January 2011 |
| NCT00425841 | Completed | Phase 2 | Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer | May 2006 | December 2009 |
| NCT00427713 | Completed | Phase 3 | Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer | November 2004 | |
| NCT00433550 | Completed | Phase 2 | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer | May 2007 | May 2016 |
| NCT00436241 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer. | March 2007 | November 2010 |
| NCT00436280 | Completed | Phase 2 | Chemotherapy for Participants With Lymphoma | February 2007 | November 2012 |
| NCT00436800 | Completed | Phase 2 | Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma | March 2005 | October 2008 |
| NCT00439426 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. | April 2007 | September 2009 |
| NCT00444678 | Completed | Phase 2 | Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | June 1, 2004 | June 1, 2015 |
| NCT00447967 | Completed | Phase 2 | Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients | July 2004 | September 2008 |
| NCT00448552 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer | February 2004 | June 2008 |
| NCT00448760 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery | October 2004 | April 2010 |
| NCT00448838 | Completed | N/A | Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | May 2006 | March 2011 |
| NCT00452374 | Completed | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | November 2004 | January 2011 |
| NCT00454636 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | March 2007 | July 2010 |
| NCT00456599 | Completed | Phase 2 | Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer | April 2007 | January 2013 |
| NCT00458809 | Completed | Phase 1 | Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer | March 2007 | November 2007 |
| NCT00001835 | Completed | Phase 1 | Oxaliplatin in Cancer Patients With Impaired Kidney Function | September 1999 | December 2001 |
| NCT00470184 | Completed | Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer | November 2006 | |
| NCT00470405 | Completed | Phase 1 | Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma | May 2004 | November 2007 |
| NCT00472849 | Completed | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | May 2007 | February 2012 |
| NCT00476086 | Completed | Phase 2 | Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus | August 2006 | December 2015 |
| NCT00483405 | Completed | Phase 2 | Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer | October 2006 | December 2010 |
| NCT00491855 | Completed | Phase 1 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | June 2007 | December 2012 |
| NCT00499850 | Completed | Phase 1 | Phase I FOLFOX Combination | August 2005 | April 2008 |
| NCT00501410 | Completed | Phase 1 | FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | April 23, 2007 | March 3, 2017 |
| NCT00503997 | Completed | Phase 2 | Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer | December 2006 | June 2010 |
| NCT00507585 | Completed | Phase 1 | Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin | June 2006 | January 2010 |
| NCT00514020 | Completed | Phase 2 | Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer | August 2007 | February 2011 |
| NCT00515216 | Completed | Phase 2 | Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors | August 2007 | November 2013 |
| NCT00517829 | Completed | Phase 2 | Docetaxel+Oxali+/-Cetux Met Gastric/GEJ | July 2007 | April 2012 |
| NCT00525785 | Completed | Phase 2 | Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | January 2004 | January 2016 |
| NCT00525915 | Completed | Phase 2 | Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | April 2005 | March 2013 |
| NCT00526110 | Completed | Phase 1/Phase 2 | Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients | August 2004 | June 2015 |
| NCT00532909 | Completed | Phase 1 | Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | July 2006 | May 2010 |
| NCT00536809 | Completed | Phase 1 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | September 26, 2007 | October 31, 2008 |
| NCT00536874 | Completed | Phase 2 | Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | October 2007 | February 2017 |
| NCT00544349 | Completed | Phase 2 | Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery | October 2006 | |
| NCT00555620 | Completed | Phase 1 | Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer | May 2008 | December 2011 |
| NCT00556413 | Completed | Phase 2 | Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | September 2005 | November 17, 2011 |
| NCT00559455 | Completed | Phase 2 | Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma | September 2007 | January 2010 |
| NCT00559676 | Completed | Phase 4 | Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer | March 2005 | |
| NCT00462501 | Completed | N/A | Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer | March 2007 | February 2014 |
| NCT00003287 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer | March 1998 | |
| NCT00003427 | Completed | Phase 1 | Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer | April 1998 | April 2002 |
| NCT00003594 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | October 1998 | October 2004 |
| NCT00003799 | Completed | Phase 1 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer | May 1999 | |
| NCT00003834 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | March 1999 | December 2005 |
| NCT00004102 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | January 1999 | |
| NCT00004126 | Completed | Phase 2 | Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer | November 1999 | August 2003 |
| NCT00004127 | Completed | Phase 2 | Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach | February 2000 | August 2003 |
| NCT00004187 | Completed | Phase 1/Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | June 1999 | April 2004 |
| NCT00004190 | Completed | Phase 2 | Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer | October 1999 | June 2003 |
| NCT00004203 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Metastatic Bladder Cancer | February 2000 | April 2005 |
| NCT00004220 | Completed | Phase 1 | Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer | October 1999 | |
| NCT00004242 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | October 1999 | |
| NCT00004243 | Completed | Phase 1 | Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor | March 2000 | |
| NCT00004257 | Completed | Phase 1 | Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer | January 2000 | January 2004 |
| NCT00004931 | Completed | Phase 3 | Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer | February 2000 | |
| NCT00005035 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer | December 1999 | March 2004 |
| NCT00005036 | Completed | Phase 3 | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | November 1999 | |
| NCT00005050 | Completed | Phase 1/Phase 2 | Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer | August 1999 | |
| NCT00005068 | Completed | Phase 1 | Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors | January 2000 | June 2003 |
| NCT00005077 | Completed | Phase 1 | Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction | February 2000 | |
| NCT00005836 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy | February 2000 | July 2004 |
| NCT00005837 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer | February 2000 | June 2004 |
| NCT00005839 | Completed | Phase 1 | Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor | August 2000 | June 2004 |
| NCT00005844 | Completed | Phase 1 | Oxaliplatin in Treating Children With Advanced Solid Tumors | April 2000 | September 2007 |
| NCT00005860 | Completed | Phase 1 | Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | April 2000 | |
| NCT00006050 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | April 4, 1999 | April 4, 2003 |
| NCT00006062 | Completed | Phase 1 | Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction | July 2000 | May 2001 |
| NCT00006094 | Completed | Phase 1/Phase 2 | Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum | July 2000 | |
| NCT00006391 | Completed | Phase 1 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | August 2000 | |
| NCT00006465 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | December 2000 | April 2005 |
| NCT00006473 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | September 2000 | |
| NCT00008060 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer | May 2000 | December 2003 |
| NCT00008294 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | August 2000 | |
| NCT00012389 | Completed | Phase 3 | Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | December 2000 | October 2008 |
| NCT00016198 | Completed | Phase 2 | Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer | May 2001 | December 2010 |
| NCT00016978 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan | April 2001 | |
| NCT00017082 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer | April 2001 | December 2010 |
| NCT00019773 | Completed | Phase 1 | Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer | July 1999 | |
| NCT00025142 | Completed | Phase 2 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | July 2001 | November 2006 |
| NCT00025337 | Completed | Phase 3 | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated | September 2001 | |
| NCT00026234 | Completed | Phase 2 | Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | February 2002 | |
| NCT00026299 | Completed | Phase 1/Phase 2 | Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer | September 2001 | February 2005 |
| NCT00034619 | Completed | Phase 2 | A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. | ||
| NCT00039208 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Colorectal Cancer | February 2002 | |
| NCT00039611 | Completed | N/A | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | May 2002 | October 2007 |
| NCT00040820 | Completed | N/A | Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | January 2002 | March 2004 |
| NCT00040859 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | September 2002 | April 2008 |
| NCT00043121 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery | June 2002 | |
| NCT00047177 | Completed | Phase 2 | Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor | October 2002 | July 2007 |
| NCT00049101 | Completed | Phase 1/Phase 2 | Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | August 2002 | August 2004 |
| NCT00052364 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Liver Cancer | September 2002 | |
| NCT00055822 | Completed | Phase 1/Phase 2 | Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer | October 2002 | October 2004 |
| NCT00056030 | Completed | Phase 2 | Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | December 2004 | |
| NCT00057863 | Completed | Phase 2 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | January 2003 | March 2010 |
| NCT00058149 | Completed | Phase 3 | Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | March 2003 | |
| NCT00060411 | Completed | Phase 1 | A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer | June 2003 | |
| NCT00061815 | Completed | Phase 3 | Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | March 2003 | November 2005 |
| NCT00062426 | Completed | Phase 3 | Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer | May 2003 | February 2011 |
| NCT00066274 | Completed | Phase 2 | Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | July 23, 2002 | April 1, 2007 |
| NCT00068692 | Completed | Phase 3 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | October 15, 2003 | November 15, 2016 |
| NCT00069108 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer | July 2003 | August 2006 |
| NCT00069121 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | April 18, 2003 | April 21, 2011 |
| NCT00070213 | Completed | Phase 3 | Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | September 2003 | June 1, 2011 |
| NCT00071929 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer | November 1999 | September 2007 |
| NCT00074321 | Completed | Phase 1 | Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors | November 2003 | |
| NCT00079274 | Completed | Phase 3 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | February 2004 | November 2012 |
| NCT00080951 | Completed | Phase 2 | Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | March 2004 | February 2008 |
| NCT00080990 | Completed | Phase 1 | Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors | February 2004 | |
| NCT00081237 | Completed | Phase 1 | OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer | February 2004 | |
| NCT00081289 | Completed | Phase 2 | Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer | March 2004 | December 2016 |
| NCT00084617 | Completed | Phase 2 | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma | March 2004 | December 2008 |
| NCT00084643 | Completed | Phase 1 | GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors | May 2004 | |
| NCT00086931 | Completed | Phase 1/Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum | September 2003 | May 2010 |
| NCT00086996 | Completed | Phase 2 | S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction | September 2004 | August 2011 |
| NCT00089024 | Completed | Phase 2 | Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | February 25, 2004 | December 1, 2014 |
| NCT00091182 | Completed | Phase 2 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | October 2004 | |
| NCT00093379 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | April 2004 | July 2012 |
| NCT00096070 | Completed | Phase 2 | Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer | December 2004 | |
| NCT00096278 | Completed | Phase 3 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | September 15, 2004 | December 31, 2012 |
| NCT00098787 | Completed | Phase 2 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | September 8, 2005 | April 2015 |
| NCT00098982 | Completed | Phase 1 | Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | September 2004 | |
| NCT00100841 | Completed | Phase 2 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | November 2004 | July 2011 |
| NCT00101270 | Completed | Phase 1 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | March 2005 | |
| NCT00103298 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | December 2004 | July 2006 |
| NCT00104689 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | June 30, 2003 | January 2008 |
| NCT00112528 | Completed | Phase 2 | Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | June 2005 | November 2010 |
| NCT00112658 | Completed | Phase 2/Phase 3 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | November 2004 | June 30, 2010 |
| NCT00112918 | Completed | Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | December 2004 | June 2012 |
| NCT00114231 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer | May 2006 | December 2014 |
| NCT00118261 | Completed | Phase 1 | Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer | March 2005 | January 2011 |
| NCT00118755 | Completed | Phase 2 | A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer | July 2005 | |
| NCT00123851 | Completed | Phase 2 | Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | March 2003 | August 2006 |
| NCT00125034 | Completed | Phase 2 | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) | July 2005 | November 2010 |
| NCT00577031 | Completed | Phase 4 | OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. | February 2008 | August 2011 |
| NCT00578071 | Completed | Phase 1/Phase 2 | Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer | December 2007 | June 2012 |
| NCT00585078 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma | May 2004 | December 2011 |
| NCT00601705 | Completed | Phase 2 | Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | January 5, 2008 | January 23, 2015 |
| NCT00602602 | Completed | Phase 2 | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | March 2007 | September 2011 |
| NCT00609336 | Completed | Phase 2 | Perioperative Therapy for Resectable Pancreatic Cancer | January 2008 | December 2016 |
| NCT00610948 | Completed | Phase 1 | Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment | March 2008 | January 2016 |
| NCT00613080 | Completed | Phase 2 | Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | April 2008 | December 2016 |
| NCT00623805 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer | March 2008 | May 2012 |
| NCT00625092 | Completed | Phase 1 | Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | October 2007 | September 2011 |
| NCT00634751 | Completed | Phase 1/Phase 2 | CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma | February 2008 | July 2010 |
| NCT00640081 | Completed | Phase 2 | Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | July 2007 | September 2015 |
| NCT00660426 | Completed | Phase 1 | Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors | March 2005 | April 2008 |
| NCT00660725 | Completed | Phase 1 | Study of GemOx and Vandetanib in Advanced Solid Malignancy | February 2009 | December 2010 |
| NCT00675012 | Completed | Phase 2 | NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer | December 2007 | May 2013 |
| NCT00686166 | Completed | Phase 2 | S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer | February 2009 | March 2018 |
| NCT00689624 | Completed | Phase 2 | Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | July 2007 | December 2010 |
| NCT00700570 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer | August 2008 | November 2011 |
| NCT00707278 | Completed | Phase 1 | Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma | September 2005 | August 2011 |
| NCT00707889 | Completed | Phase 2 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | October 2008 | May 2012 |
| NCT00711243 | Completed | Phase 1/Phase 2 | Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | April 20, 2005 | February 25, 2011 |
| NCT00719797 | Completed | Phase 3 | Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | July 2008 | |
| NCT00737373 | Completed | Phase 2 | Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer | August 2007 | March 2011 |
| NCT00749450 | Completed | Phase 3 | Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer | March 2008 | |
| NCT00766155 | Completed | Phase 3 | Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer | August 2008 | |
| NCT00769405 | Completed | Phase 3 | Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer | February 2008 | |
| NCT00778102 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | October 2008 | October 2013 |
| NCT00803647 | Completed | Phase 2 | A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | January 2010 | November 2014 |
| NCT00816543 | Completed | Phase 2 | Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma | December 2008 | May 2012 |
| NCT00828672 | Completed | Phase 2 | Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer | June 2009 | March 2019 |
| NCT00831181 | Completed | Phase 2 | Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer | July 2004 | November 2009 |
| NCT00835185 | Completed | Phase 2 | Study of IMC-11F8 in Participants With Colorectal Cancer | August 2007 | October 2010 |
| NCT00846482 | Completed | N/A | Exploratory Study Of The ERCC-1 Gene | February 2008 | December 2018 |
| NCT00849615 | Completed | Phase 2 | Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2009 | January 2016 |
| NCT00851084 | Completed | Phase 2 | Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer | February 2009 | January 2012 |
| NCT00859469 | Completed | Phase 2 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | April 2004 | March 2013 |
| NCT00861094 | Completed | Phase 2/Phase 3 | Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer | March 2008 | December 2012 |
| NCT00862784 | Completed | Phase 2 | A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer | April 2009 | August 2011 |
| NCT00865189 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer | October 23, 2007 | March 23, 2016 |
| NCT00909987 | Completed | Phase 2 | Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum | March 2009 | June 2013 |
| NCT00920868 | Completed | Phase 1 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | May 2009 | August 2014 |
| NCT00932438 | Completed | Phase 1/Phase 2 | Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab | June 2009 | December 2012 |
| NCT00938470 | Completed | Phase 2 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | January 2010 | March 2018 |
| NCT00940303 | Completed | Phase 2 | OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | June 2009 | February 2014 |
| NCT00941655 | Completed | Phase 3 | Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial | July 22, 2009 | June 18, 2012 |
| NCT00941967 | Completed | Phase 2 | Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer | December 2008 | December 2012 |
| NCT00957905 | Completed | Phase 2 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | June 2009 | August 2014 |
| NCT00975897 | Completed | Phase 2/Phase 3 | Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | July 2009 | December 2012 |
| NCT00980239 | Completed | Phase 1 | HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | September 2009 | August 2015 |
| NCT00982592 | Completed | Phase 2 | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | September 2009 | October 2014 |
| NCT00987766 | Completed | Phase 1 | Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer | November 2009 | October 2016 |
| NCT01013805 | Completed | Phase 2 | Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer | November 2009 | December 2012 |
| NCT01022541 | Completed | Phase 2 | Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer | June 2006 | February 2015 |
| NCT01024504 | Completed | Phase 2 | Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer | March 2006 | March 2010 |
| NCT01039155 | Completed | Phase 1 | Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy | December 2009 | July 2015 |
| NCT01042691 | Completed | Phase 1 | Isolated Liver Perfusion With Oxaliplatin | May 2003 | November 2011 |
| NCT01048320 | Completed | Phase 1 | Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer | July 2006 | December 2010 |
| NCT01060007 | Completed | Phase 2 | Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer | November 2009 | September 2014 |
| NCT01077739 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin | July 2009 | January 2012 |
| NCT01099449 | Completed | Phase 3 | Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy | June 2010 | March 2013 |
| NCT01108107 | Completed | Phase 2 | Neoadjuvant Treatment of Colon Cancer | April 2010 | March 2015 |
| NCT01121848 | Completed | Phase 3 | Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | July 2010 | October 2013 |
| NCT01130337 | Completed | Phase 2 | A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer | July 2010 | June 2014 |
| NCT01159171 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. | January 2006 | July 2010 |
| NCT01163396 | Completed | Phase 2 | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer | July 2007 | April 2010 |
| NCT01164215 | Completed | Phase 1 | Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy | February 2010 | September 2013 |
| NCT01178944 | Completed | Phase 2 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | September 2010 | November 2015 |
| NCT01183663 | Completed | Phase 1 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | August 2010 | May 2016 |
| NCT01193517 | Completed | Phase 1/Phase 2 | Azacitidine and CAPOX in Metastatic Colorectal Cancer | August 2010 | November 2016 |
| NCT01197560 | Completed | Phase 2/Phase 3 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | September 2, 2010 | April 5, 2018 |
| NCT01206049 | Completed | Phase 2 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | September 2010 | March 2016 |
| NCT01206530 | Completed | Phase 1/Phase 2 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | September 2010 | September 2017 |
| NCT01208103 | Completed | Phase 2 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | May 6, 2011 | March 7, 2018 |
| NCT01212822 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | April 27, 2011 | January 3, 2018 |
| NCT01213238 | Completed | Phase 1 | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | September 30, 2010 | September 26, 2018 |
| NCT01216644 | Completed | Phase 2/Phase 3 | 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | August 2010 | May 2019 |
| NCT01222312 | Completed | Phase 2 | Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel | August 2008 | November 2011 |
| NCT01225744 | Completed | Phase 2 | Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | April 2009 | May 2013 |
| NCT01226719 | Completed | Phase 2 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | December 2010 | March 2014 |
| NCT01228734 | Completed | Phase 3 | A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients | September 9, 2010 | January 31, 2018 |
| NCT01231399 | Completed | Phase 1/Phase 2 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | February 2012 | July 2016 |
| NCT01246960 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer | April 2011 | May 2014 |
| NCT01262482 | Completed | Phase 2 | Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment | October 2008 | December 2011 |
| NCT01263171 | Completed | Phase 2 | Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery | April 2012 | November 2015 |
| NCT01289821 | Completed | Phase 2 | First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib | February 2011 | June 2014 |
| NCT01295086 | Completed | N/A | Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer | March 2011 | January 2018 |
| NCT01308840 | Completed | Phase 2 | Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer | December 2010 | January 2013 |
| NCT01313377 | Completed | Phase 3 | Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery | July 2009 | June 2016 |
| NCT01333033 | Completed | Phase 2 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | July 2011 | April 1, 2023 |
| NCT01338792 | Completed | Phase 2 | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | June 2006 | December 2012 |
| NCT01348412 | Completed | Phase 2 | Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure | December 15, 2010 | April 18, 2018 |
| NCT01362374 | Completed | Phase 1 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | July 11, 2011 | October 16, 2020 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01383707 | Completed | Phase 2 | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer | August 12, 2011 | May 18, 2016 |
| NCT01386346 | Completed | Phase 1 | Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer | June 2011 | September 2018 |
| NCT01399190 | Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer | July 2011 | February 2014 | |
| NCT01399684 | Completed | Phase 2 | A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | November 2011 | February 2014 |
| NCT01413022 | Completed | Phase 1 | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | April 2012 | September 2016 |
| NCT01442155 | Completed | An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer | October 2011 | April 2015 | |
| NCT01442649 | Completed | Phase 2 | Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | December 2010 | December 31, 2017 |
| NCT01442935 | Completed | Phase 2 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | February 2011 | January 2021 |
| NCT01443065 | Completed | Phase 2 | MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma | January 2011 | September 2018 |
| NCT01481545 | Completed | Phase 2 | Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer | December 2006 | December 2016 |
| NCT01481701 | Completed | Phase 2 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | October 2008 | May 2014 |
| NCT01490866 | Completed | Phase 2 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | January 2012 | July 2015 |
| NCT01498289 | Completed | Phase 2 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | February 2012 | September 19, 2019 |
| NCT01503983 | Completed | Phase 2 | Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive | August 2011 | May 2015 |
| NCT01505413 | Completed | Phase 2 | Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer | January 2011 | March 2014 |
| NCT01531452 | Completed | Phase 2 | The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer | June 2011 | June 2013 |
| NCT01554059 | Completed | Phase 2 | Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients | March 2012 | August 2014 |
| NCT01558869 | Completed | Phase 2 | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | April 2012 | December 2016 |
| NCT01560949 | Completed | Phase 2 | Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | June 14, 2012 | February 20, 2019 |
| NCT01561014 | Completed | Phase 1 | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | April 2007 | March 2009 |
| NCT01580410 | Completed | Phase 2 | Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix | May 2009 | November 2016 |
| NCT01588990 | Completed | Phase 4 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | June 26, 2012 | September 30, 2016 |
| NCT01590719 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer | July 2012 | October 2014 |
| NCT01630083 | Completed | Phase 2 | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | July 19, 2012 | January 31, 2019 |
| NCT01633970 | Completed | Phase 1 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | July 11, 2012 | February 26, 2020 |
| NCT01643499 | Completed | Phase 1 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | March 26, 2012 | July 2019 |
| NCT01650428 | Completed | Phase 2 | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | April 2013 | February 14, 2019 |
| NCT01658943 | Completed | Phase 2 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | August 2012 | June 2015 |
| NCT01660711 | Completed | Phase 2 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | July 2012 | August 22, 2018 |
| NCT01662869 | Completed | Phase 3 | A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | November 2012 | December 2015 |
| NCT01666730 | Completed | Phase 2 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | February 21, 2013 | August 1, 2018 |
| NCT01671449 | Completed | Phase 3 | S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer | December 2012 | October 2015 |
| NCT01710592 | Completed | Phase 2 | A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer | May 2007 | |
| NCT01711242 | Completed | Phase 2 | Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma | January 2012 | January 2021 |
| NCT01718873 | Completed | Phase 3 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer | May 2012 | December 2019 |
| NCT01726452 | Completed | Phase 3 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | January 24, 2013 | August 4, 2022 |
| NCT01747551 | Completed | Phase 2 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | January 2013 | July 26, 2017 |
| NCT01748773 | Completed | Phase 2 | A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer | January 29, 2013 | June 15, 2017 |
| NCT01775501 | Completed | Phase 2 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | January 2013 | December 2019 |
| NCT01803282 | Completed | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | March 29, 2013 | April 23, 2019 |
| NCT01821612 | Completed | Early Phase 1 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer | May 2013 | June 15, 2018 |
| NCT01824459 | Completed | Phase 3 | S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients | April 2013 | December 1, 2018 |
| NCT01835041 | Completed | Phase 1 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | April 2013 | March 16, 2023 |
| NCT01858649 | Completed | Phase 2 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. | May 2013 | May 2019 |
| NCT01867697 | Completed | Phase 2 | Nordic 8 - A Phase II Trial | May 2012 | March 2019 |
| NCT01896531 | Completed | Phase 2 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | August 14, 2013 | January 26, 2021 |
| NCT01913639 | Completed | Phase 2 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | July 2013 | June 2019 |
| NCT01926197 | Completed | Phase 3 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | August 14, 2013 | September 30, 2022 |
| NCT01926236 | Completed | Phase 3 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers | February 2014 | January 2019 |
| NCT01928290 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | November 8, 2013 | October 28, 2019 |
| NCT01959139 | Completed | Phase 1/Phase 2 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | January 23, 2014 | November 9, 2023 |
| NCT02024607 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | January 2014 | November 2019 |
| NCT02035072 | Completed | Phase 2 | Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. | November 2010 | December 2016 |
| NCT02041481 | Completed | Phase 1 | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | June 2014 | January 19, 2018 |
| NCT02062749 | Completed | Phase 1 | Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma | May 19, 2014 | June 27, 2018 |
| NCT02071043 | Completed | Phase 2 | Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis | November 2008 | January 2013 |
| NCT02077998 | Completed | Early Phase 1 | Oxaliplatin in Treating Patients With Metastatic Breast Cancer | May 2015 | December 2015 |
| NCT02119026 | Completed | Phase 2 | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer | February 2011 | August 31, 2017 |
| NCT02172976 | Completed | Phase 2/Phase 3 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | November 2014 | May 2020 |
| NCT02181218 | Completed | Phase 1 | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | February 4, 2015 | June 26, 2020 |
| NCT02231723 | Completed | Phase 1 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | August 2014 | June 2020 |
| NCT02244632 | Completed | Phase 1/Phase 2 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | September 2014 | January 30, 2020 |
| NCT02246049 | Completed | Phase 2 | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC | May 2014 | February 2017 |
| NCT02270606 | Completed | Phase 1 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | December 4, 2014 | May 13, 2021 |
| NCT02287129 | Completed | Phase 2 | Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction | December 5, 2014 | August 7, 2020 |
| NCT02319018 | Completed | Phase 1 | Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors | August 27, 2015 | September 29, 2018 |
| NCT02340949 | Completed | Phase 2 | Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer | January 2015 | February 4, 2020 |
| NCT02348216 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | April 21, 2015 | July 27, 2023 |
| NCT02359058 | Completed | Phase 1 | A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer | February 2015 | November 2016 |
| NCT02387138 | Completed | Phase 1 | A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan | April 2014 | September 2018 |
| NCT02395640 | Completed | Phase 3 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | March 2015 | February 23, 2021 |
| NCT02412683 | Completed | Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer | January 2014 | September 2016 | |
| NCT02539225 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | October 5, 2015 | March 10, 2021 |
| NCT02539537 | Completed | Phase 3 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | October 23, 2015 | September 25, 2023 |
| NCT02545504 | Completed | Phase 3 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | October 13, 2015 | May 15, 2019 |
| NCT02551991 | Completed | Phase 2 | Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | October 19, 2015 | February 15, 2021 |
| NCT02558868 | Completed | Phase 2 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | September 1, 2015 | December 31, 2017 |
| NCT02560974 | Completed | Phase 3 | A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer | June 2006 | November 2012 |
| NCT02562716 | Completed | Phase 2 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | January 6, 2016 | September 26, 2022 |
| NCT02569723 | Completed | N/A | Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy | October 16, 2015 | April 4, 2020 |
| NCT02582970 | Completed | Phase 4 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | May 2005 | April 2008 |
| NCT02607982 | Completed | Phase 2 | CCRT for Esophageal Cancer. | January 2005 | November 2015 |
| NCT02620800 | Completed | Phase 1 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | January 18, 2016 | October 29, 2018 |
| NCT02620865 | Completed | Phase 1/Phase 2 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | December 2015 | June 21, 2021 |
| NCT02625610 | Completed | Phase 3 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | December 24, 2015 | June 3, 2021 |
| NCT02641691 | Completed | Phase 2 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum | May 27, 2016 | March 29, 2020 |
| NCT02661971 | Completed | Phase 2/Phase 3 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | June 2016 | June 20, 2022 |
| NCT02694718 | Completed | Phase 2 | A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | March 2005 | November 2006 |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT02716766 | Completed | Phase 2 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | March 2016 | September 2018 |
| NCT02720068 | Completed | Phase 1 | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | May 2, 2016 | March 15, 2024 |
| NCT02725424 | Completed | Phase 2 | Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer | August 2015 | June 2019 |
| NCT02730546 | Completed | Phase 1/Phase 2 | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | June 24, 2016 | October 31, 2023 |
| NCT02735239 | Completed | Phase 1/Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | June 24, 2016 | June 16, 2022 |
| NCT02741388 | Completed | Phase 1 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | October 2016 | September 29, 2021 |
| NCT02746796 | Completed | Phase 2/Phase 3 | Study of ONO-4538 in Gastric Cancer | March 2016 | November 17, 2022 |
| NCT02833753 | Completed | Phase 1 | Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI | July 2016 | February 2022 |
| NCT02848443 | Completed | Phase 1 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | May 2016 | April 9, 2020 |
| NCT02860234 | Completed | Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment | August 2016 | November 2019 | |
| NCT02864849 | Completed | Phase 2 | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | August 2016 | June 2019 |
| NCT02879227 | Completed | Phase 2 | Radiochemotherapy in Elderly Patients With Oesophagus Cancer | January 2010 | December 2014 |
| NCT02896907 | Completed | Early Phase 1 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | October 18, 2016 | March 2019 |
| NCT02921256 | Completed | Phase 2 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | January 11, 2017 | September 20, 2023 |
| NCT02954536 | Completed | Phase 2 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | November 3, 2016 | March 14, 2023 |
| NCT02970526 | Completed | Long Term Effect of Oxaliplatin Treatment in Cancer Survivors | July 2016 | August 29, 2019 | |
| NCT03000374 | Completed | Phase 2 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery | May 30, 2017 | December 15, 2021 |
| NCT03006705 | Completed | Phase 3 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | January 31, 2017 | March 31, 2023 |
| NCT03043729 | Completed | Phase 2 | mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | March 6, 2017 | June 1, 2022 |
| NCT03085914 | Completed | Phase 1/Phase 2 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | May 2, 2017 | July 13, 2020 |
| NCT03111732 | Completed | Phase 2 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | June 14, 2017 | November 8, 2021 |
| NCT03121807 | Completed | N/A | Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer | September 1, 2014 | June 1, 2019 |
| NCT03146377 | Completed | Phase 2 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | April 2014 | December 2016 |
| NCT03159143 | Completed | Phase 2 | Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract | December 17, 2004 | December 2, 2009 |
| NCT03162510 | Completed | Phase 1 | Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers | June 26, 2018 | January 31, 2022 |
| NCT03231722 | Completed | Phase 3 | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS | September 13, 2017 | June 24, 2022 |
| NCT03253133 | Completed | Phase 1 | Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC | May 10, 2016 | April 24, 2023 |
| NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
| NCT03336216 | Completed | Phase 2 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | December 19, 2017 | June 1, 2023 |
| NCT03365765 | Completed | Phase 3 | mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer | February 12, 2018 | December 31, 2022 |
| NCT03374254 | Completed | Phase 1 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | February 16, 2018 | July 18, 2023 |
| NCT03382600 | Completed | Phase 2 | Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) | March 26, 2018 | May 30, 2021 |
| NCT03414983 | Completed | Phase 2/Phase 3 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | February 20, 2018 | December 28, 2022 |
| NCT03451331 | Completed | Phase 2 | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | May 10, 2018 | July 28, 2023 |
| NCT03469557 | Completed | Phase 2 | BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma | July 18, 2017 | August 19, 2020 |
| NCT03472365 | Completed | Phase 2 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | April 2, 2018 | November 25, 2020 |
| NCT03493061 | Completed | Phase 2 | A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | February 1, 2018 | December 30, 2022 |
| NCT03578874 | Completed | Phase 2 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | June 20, 2016 | April 30, 2019 |
| NCT03607656 | Completed | Phase 2/Phase 3 | The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer | June 8, 2018 | November 30, 2023 |
| NCT03611556 | Completed | Phase 1/Phase 2 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | June 21, 2018 | July 22, 2022 |
| NCT03698461 | Completed | Phase 2 | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | May 15, 2019 | October 24, 2023 |
| NCT03721653 | Completed | Phase 2 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | November 30, 2018 | August 31, 2023 |
| NCT03745170 | Completed | Phase 3 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | December 19, 2018 | October 21, 2022 |
| NCT03778593 | Completed | Phase 2 | FOLFIRINOX for 2nd-line Treatment of BTC | March 1, 2019 | January 14, 2021 |
| NCT03783936 | Completed | Phase 2 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | January 24, 2019 | August 30, 2022 |
| NCT03802591 | Completed | Phase 3 | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | March 28, 2019 | September 22, 2023 |
| NCT04009876 | Completed | Phase 2 | A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer | May 1, 2019 | October 21, 2022 |
| NCT04080843 | Completed | Phase 2 | Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | November 15, 2019 | July 1, 2022 |
| NCT04313608 | Completed | Phase 1 | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | June 4, 2020 | October 26, 2021 |
| NCT04417699 | Completed | Phase 2 | SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer | July 5, 2022 | February 21, 2024 |
| NCT04694183 | Completed | Phase 2 | The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | August 17, 2020 | May 6, 2023 |
| NCT04808791 | Completed | Phase 2 | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 27, 2021 | July 21, 2023 |
| NCT05997524 | Completed | Phase 2 | Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. | March 1, 2021 | June 30, 2023 |
| NCT05350943 | Enrolling by invitation | Phase 2 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | March 1, 2022 | November 2023 |
| NCT04135313 | Enrolling by invitation | Phase 3 | Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer | October 20, 2019 | October 2024 |
| NCT04103697 | Enrolling by invitation | Phase 3 | Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer | August 1, 2019 | August 2024 |
| NCT04134897 | Enrolling by invitation | Phase 3 | Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer | October 14, 2019 | October 2024 |
| NCT05914610 | Not yet recruiting | Phase 3 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | September 1, 2023 | July 30, 2028 |
| NCT05524974 | Not yet recruiting | Phase 2 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | September 1, 2022 | September 1, 2027 |
| NCT06383078 | Not yet recruiting | Phase 2 | HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer | April 20, 2024 | December 30, 2027 |
| NCT05700448 | Not yet recruiting | Phase 3 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | July 2024 | November 2028 |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT06368141 | Not yet recruiting | Phase 2 | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | May 1, 2024 | April 30, 2026 |
| NCT04850040 | Not yet recruiting | Phase 2 | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | May 6, 2021 | December 31, 2024 |
| NCT06245356 | Not yet recruiting | Phase 2 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | June 20, 2024 | June 21, 2028 |
| NCT05640726 | Not yet recruiting | Phase 2 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | May 1, 2023 | May 1, 2026 |
| NCT06166589 | Not yet recruiting | Phase 2 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | January 1, 2024 | January 1, 2027 |
| NCT05970627 | Not yet recruiting | Phase 2 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | July 28, 2023 | July 28, 2029 |
| NCT05974059 | Not yet recruiting | Phase 2 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | August 1, 2023 | August 1, 2024 |
| NCT06259058 | Not yet recruiting | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | April 1, 2024 | December 1, 2027 |
| NCT06447662 | Not yet recruiting | Phase 1 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | July 28, 2024 | July 12, 2028 |
| NCT05493332 | Not yet recruiting | Phase 2 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | September 2022 | September 2024 |
| NCT05346874 | Not yet recruiting | Phase 2 | Neoadjuvant TACiE in Locally Advanced Gastric Cancer | June 1, 2022 | May 1, 2025 |
| NCT05111444 | Not yet recruiting | Phase 2 | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 31, 2021 | June 30, 2024 |
| NCT06268015 | Not yet recruiting | Phase 2 | Botensilimab and Balstilimab Optimization in Colorectal Cancer | July 2024 | July 2028 |
| NCT05608785 | Not yet recruiting | Phase 1/Phase 2 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | January 1, 2023 | October 1, 2024 |
| NCT04663763 | Not yet recruiting | Phase 2 | Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer | December 1, 2020 | December 1, 2025 |
| NCT05774964 | Not yet recruiting | Phase 2 | Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases | March 15, 2023 | March 15, 2025 |
| NCT05720559 | Not yet recruiting | Phase 2 | Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection | March 1, 2023 | September 1, 2026 |
| NCT05846867 | Not yet recruiting | Phase 1/Phase 2 | Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients | May 10, 2023 | July 10, 2025 |
| NCT05794750 | Not yet recruiting | Phase 2 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） | April 24, 2023 | April 24, 2027 |
| NCT05396326 | Not yet recruiting | Phase 1 | A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer | June 1, 2022 | December 31, 2025 |
| NCT05479240 | Not yet recruiting | Phase 2 | Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer | September 1, 2023 | June 1, 2028 |
| NCT04488159 | Not yet recruiting | Phase 3 | Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | December 1, 2024 | June 1, 2026 |
| NCT06197438 | Not yet recruiting | Phase 2 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | January 1, 2024 | April 1, 2025 |
| NCT06204094 | Not yet recruiting | Phase 2 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer | March 1, 2024 | September 1, 2028 |
| NCT06205485 | Not yet recruiting | Phase 3 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | July 31, 2024 | June 30, 2030 |
| NCT05047991 | Not yet recruiting | Phase 2 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | October 2021 | November 2024 |
| NCT05699746 | Not yet recruiting | Phase 3 | CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD | March 2023 | December 2026 |
| NCT06310473 | Not yet recruiting | Phase 2 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | March 2024 | March 2028 |
| NCT06447636 | Not yet recruiting | Phase 2 | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | August 1, 2024 | August 2028 |
| NCT06446388 | Not yet recruiting | Phase 2 | Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | June 30, 2024 | December 1, 2027 |
| NCT05314998 | Not yet recruiting | Phase 3 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | June 15, 2024 | September 1, 2031 |
| NCT06210360 | Not yet recruiting | Phase 2 | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX | February 1, 2024 | April 1, 2027 |
| NCT06041035 | Not yet recruiting | Phase 1/Phase 2 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | October 2023 | October 2025 |
| NCT06333769 | Not yet recruiting | Phase 2 | A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer | June 1, 2024 | December 1, 2026 |
| NCT04443543 | Not yet recruiting | Phase 2 | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer | June 22, 2020 | December 31, 2026 |
| NCT06390982 | Not yet recruiting | Phase 2 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | May 2024 | December 2028 |
| NCT05732493 | Not yet recruiting | Phase 2 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) | March 1, 2023 | December 31, 2024 |
| NCT05296005 | Not yet recruiting | Phase 1 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | May 31, 2022 | December 31, 2024 |
| NCT05585814 | Not yet recruiting | Phase 2 | Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer | October 2022 | October 2025 |
| NCT06381154 | Not yet recruiting | Phase 2 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | June 30, 2024 | July 4, 2029 |
| NCT06396585 | Not yet recruiting | Phase 2 | The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction | August 1, 2024 | August 31, 2026 |
| NCT06225999 | Not yet recruiting | Phase 2 | Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas | March 31, 2024 | January 1, 2026 |
| NCT05877573 | Recruiting | N/A | Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer | July 1, 2023 | August 1, 2026 |
| NCT05891171 | Recruiting | Phase 1 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | October 13, 2023 | August 2025 |
| NCT01628211 | Recruiting | Phase 2 | Second Look Laparoscopy in Colorectal Cancer | April 2012 | December 2024 |
| NCT05914389 | Recruiting | Phase 2 | Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer | August 2023 | August 2030 |
| NCT05945823 | Recruiting | Phase 2 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | July 13, 2023 | May 2025 |
| NCT05960955 | Recruiting | Phase 2 | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | November 13, 2023 | November 30, 2027 |
| NCT05972655 | Recruiting | Phase 2 | Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer | August 2, 2023 | May 1, 2026 |
| NCT06462053 | Recruiting | Phase 2 | Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer | April 1, 2024 | March 1, 2027 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT06011772 | Recruiting | Early Phase 1 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | December 4, 2023 | December 4, 2026 |
| NCT05254899 | Recruiting | Phase 2 | Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL | October 1, 2021 | September 30, 2024 |
| NCT05253651 | Recruiting | Phase 3 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | October 24, 2022 | April 30, 2028 |
| NCT06017583 | Recruiting | Phase 3 | Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer | September 1, 2023 | August 31, 2026 |
| NCT05546853 | Recruiting | Phase 1 | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | March 28, 2023 | November 28, 2025 |
| NCT05239741 | Recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | April 2, 2022 | November 10, 2026 |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT05237349 | Recruiting | Phase 2 | Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma | March 1, 2022 | December 1, 2024 |
| NCT05651594 | Recruiting | Phase 2 | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma | March 7, 2023 | March 30, 2026 |
| NCT06078709 | Recruiting | Phase 2 | Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma | November 20, 2023 | November 30, 2026 |
| NCT05236972 | Recruiting | Phase 3 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | January 1, 2022 | December 31, 2028 |
| NCT06094140 | Recruiting | Phase 2 | NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer | May 20, 2022 | June 2026 |
| NCT06109467 | Recruiting | Phase 2 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | January 12, 2024 | April 2028 |
| NCT05235542 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | July 12, 2022 | March 2024 |
| NCT05223088 | Recruiting | Phase 2 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | October 31, 2021 | April 30, 2024 |
| NCT05177133 | Recruiting | Phase 2 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | November 5, 2021 | November 4, 2029 |
| NCT06124378 | Recruiting | Phase 2 | Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer | November 13, 2023 | November 30, 2026 |
| NCT05567835 | Recruiting | Phase 2 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | March 6, 2024 | January 2029 |
| NCT05171647 | Recruiting | Phase 3 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | April 25, 2022 | November 30, 2027 |
| NCT05677490 | Recruiting | Phase 3 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | January 23, 2023 | November 8, 2028 |
| NCT05610163 | Recruiting | Phase 2 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | December 8, 2022 | September 2032 |
| NCT06155383 | Recruiting | Phase 2 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | November 27, 2023 | December 31, 2027 |
| NCT02997228 | Recruiting | Phase 3 | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | January 19, 2018 | November 30, 2024 |
| NCT05161572 | Recruiting | Phase 2 | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer | September 28, 2021 | September 30, 2026 |
| NCT05152147 | Recruiting | Phase 3 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | December 2, 2021 | February 1, 2026 |
| NCT06177041 | Recruiting | Phase 3 | M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | December 25, 2023 | April 11, 2027 |
| NCT05139017 | Recruiting | Phase 2/Phase 3 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | January 14, 2022 | June 21, 2027 |
| NCT05687357 | Recruiting | Phase 2 | Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | March 15, 2023 | August 31, 2027 |
| NCT05536102 | Recruiting | Phase 2 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | September 5, 2022 | September 30, 2027 |
| NCT06196554 | Recruiting | Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs | May 1, 2023 | June 28, 2024 | |
| NCT05067283 | Recruiting | Phase 1 | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | December 17, 2021 | August 19, 2026 |
| NCT05699655 | Recruiting | Phase 2/Phase 3 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | May 10, 2023 | April 1, 2027 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT06206733 | Recruiting | Phase 3 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | January 25, 2024 | December 30, 2028 |
| NCT05026905 | Recruiting | Phase 2 | A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | December 28, 2021 | December 31, 2027 |
| NCT06208462 | Recruiting | Phase 2 | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | March 25, 2024 | January 2027 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05002686 | Recruiting | Phase 2/Phase 3 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | August 7, 2021 | August 1, 2024 |
| NCT05000697 | Recruiting | N/A | Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait | July 14, 2021 | April 2027 |
| NCT04997837 | Recruiting | Phase 3 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | July 21, 2021 | October 21, 2027 |
| NCT05611034 | Recruiting | Phase 1 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | February 6, 2023 | January 1, 2032 |
| NCT04982939 | Recruiting | Phase 2 | Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer | June 21, 2021 | June 21, 2024 |
| NCT04949256 | Recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | July 28, 2021 | December 29, 2025 |
| NCT03203525 | Recruiting | Phase 1 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | June 23, 2020 | December 31, 2026 |
| NCT04927780 | Recruiting | Phase 3 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | September 7, 2021 | July 2029 |
| NCT04891289 | Recruiting | Phase 2 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | May 7, 2021 | May 2025 |
| NCT06225622 | Recruiting | Phase 1 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | March 11, 2024 | May 1, 2026 |
| NCT04864067 | Recruiting | Phase 2 | No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer | June 9, 2021 | May 30, 2025 |
| NCT04863430 | Recruiting | Phase 2 | Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach | May 11, 2021 | December 2025 |
| NCT04861558 | Recruiting | Phase 3 | Efficacy of Hyperthermic Intraperitoneal Chemotherapy | May 1, 2021 | December 2029 |
| NCT05504252 | Recruiting | Phase 2 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin | October 5, 2022 | December 30, 2027 |
| NCT05498766 | Recruiting | Effect and Safety of Adjuvant Huaier Granule Versus Standard Chemotherapy Regimens in Gastric Cancer Patients | October 12, 2023 | June 30, 2028 | |
| NCT04847063 | Recruiting | Phase 1 | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | October 19, 2021 | December 30, 2031 |
| NCT04840264 | Recruiting | Phase 2 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | January 7, 2022 | June 30, 2027 |
| NCT05701436 | Recruiting | Phase 3 | Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial | September 1, 2022 | March 1, 2026 |
| NCT06256328 | Recruiting | Phase 2 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | December 6, 2023 | December 31, 2027 |
| NCT04821284 | Recruiting | Phase 1/Phase 2 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | December 6, 2021 | January 31, 2025 |
| NCT03366155 | Recruiting | Phase 2 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | June 24, 2019 | December 30, 2030 |
| NCT04819971 | Recruiting | Phase 2 | Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | December 1, 2021 | December 31, 2025 |
| NCT06266832 | Recruiting | Phase 2 | The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | January 1, 2024 | December 31, 2027 |
| NCT05482893 | Recruiting | Phase 1/Phase 2 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | March 15, 2023 | April 2026 |
| NCT03403101 | Recruiting | Phase 2 | The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer | July 1, 2020 | July 1, 2024 |
| NCT06269978 | Recruiting | Phase 1 | Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | June 30, 2024 | December 31, 2025 |
| NCT03418038 | Recruiting | Phase 2 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | March 23, 2018 | March 2026 |
| NCT03421288 | Recruiting | Phase 2 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | September 14, 2018 | December 31, 2027 |
| NCT06455124 | Recruiting | Phase 2 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | May 8, 2024 | December 30, 2029 |
| NCT04787354 | Recruiting | Phase 3 | Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) | November 1, 2021 | December 31, 2027 |
| NCT04745988 | Recruiting | Phase 2 | An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer | November 11, 2021 | August 2027 |
| NCT06280495 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | February 1, 2024 | December 31, 2028 |
| NCT04703101 | Recruiting | Phase 1 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | February 11, 2021 | October 15, 2026 |
| NCT06282445 | Recruiting | Phase 2 | Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | March 1, 2024 | March 31, 2026 |
| NCT06451211 | Recruiting | Phase 2 | Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer | May 17, 2023 | November 2027 |
| NCT05727163 | Recruiting | Phase 2 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | July 29, 2022 | December 31, 2026 |
| NCT05627635 | Recruiting | Phase 1/Phase 2 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | May 3, 2023 | April 1, 2025 |
| NCT02366819 | Recruiting | Phase 4 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | December 11, 2014 | June 8, 2025 |
| NCT06313801 | Recruiting | Phase 2 | Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions | January 19, 2023 | January 19, 2026 |
| NCT05564403 | Recruiting | Phase 2 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | February 9, 2024 | January 21, 2025 |
| NCT04668976 | Recruiting | Phase 2 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | November 25, 2020 | December 2024 |
| NCT05729646 | Recruiting | Phase 2 | Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | May 31, 2023 | February 28, 2029 |
| NCT03505320 | Recruiting | Phase 2 | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma | June 29, 2018 | December 31, 2026 |
| NCT05564377 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | April 7, 2023 | July 1, 2030 |
| NCT05731726 | Recruiting | Phase 2 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | February 22, 2023 | February 20, 2025 |
| NCT05412082 | Recruiting | Phase 1 | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | October 5, 2022 | October 2027 |
| NCT04447352 | Recruiting | Phase 3 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) | December 17, 2020 | May 1, 2027 |
| NCT03764553 | Recruiting | Phase 2 | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | May 1, 2019 | August 1, 2024 |
| NCT04442984 | Recruiting | Phase 2 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) | November 3, 2019 | November 3, 2024 |
| NCT05628038 | Recruiting | Phase 2 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer | August 18, 2022 | December 1, 2025 |
| NCT05382442 | Recruiting | Phase 2 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | July 27, 2022 | December 25, 2026 |
| NCT03784326 | Recruiting | Phase 2 | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma | February 19, 2019 | December 31, 2024 |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT04408638 | Recruiting | Phase 3 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | February 23, 2021 | April 15, 2025 |
| NCT03800693 | Recruiting | Phase 2 | 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers | March 14, 2019 | November 4, 2024 |
| NCT06417476 | Recruiting | Phase 2 | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | December 12, 2022 | December 2025 |
| NCT04393584 | Recruiting | Phase 2/Phase 3 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma | January 29, 2019 | January 1, 2026 |
| NCT04384484 | Recruiting | Phase 3 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | September 16, 2020 | June 30, 2028 |
| NCT04379596 | Recruiting | Phase 2 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | June 3, 2020 | July 30, 2026 |
| NCT05379595 | Recruiting | Phase 1/Phase 2 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | July 29, 2022 | April 27, 2027 |
| NCT03878472 | Recruiting | Phase 2 | Neoadjuvant Immunotherapy for Resectable Gastric Cancer | April 1, 2019 | December 31, 2024 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT03950154 | Recruiting | Phase 3 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | June 1, 2019 | August 1, 2023 |
| NCT03961867 | Recruiting | Phase 3 | Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma | September 15, 2020 | September 2025 |
| NCT03977233 | Recruiting | Phase 2 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | June 12, 2019 | January 2030 |
| NCT04365036 | Recruiting | Phase 3 | A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) | May 2020 | June 2025 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT04358354 | Recruiting | Phase 3 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | October 22, 2020 | December 31, 2024 |
| NCT04008030 | Recruiting | Phase 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | August 5, 2019 | June 10, 2026 |
| NCT04354662 | Recruiting | Phase 2 | Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer | September 26, 2019 | June 30, 2024 |
| NCT06441565 | Recruiting | Phase 2/Phase 3 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | May 24, 2024 | December 30, 2029 |
| NCT05766605 | Recruiting | Phase 3 | Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial | January 1, 2023 | January 30, 2026 |
| NCT04340141 | Recruiting | Phase 3 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | July 1, 2020 | November 2030 |
| NCT04329494 | Recruiting | Phase 1 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | August 21, 2020 | December 30, 2025 |
| NCT05802056 | Recruiting | Phase 1 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | November 29, 2023 | January 2026 |
| NCT05815303 | Recruiting | Phase 2 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | March 29, 2023 | March 2026 |
| NCT05836584 | Recruiting | Phase 2 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | December 6, 2023 | October 31, 2027 |
| NCT04262687 | Recruiting | Phase 2 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | April 6, 2021 | September 30, 2024 |
| NCT04119622 | Recruiting | Phase 2 | Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | October 8, 2019 | October 2024 |
| NCT04135781 | Recruiting | Phase 3 | Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | March 1, 2020 | October 31, 2024 |
| NCT04137107 | Recruiting | Phase 2/Phase 3 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | June 17, 2020 | December 31, 2025 |
| NCT04141995 | Recruiting | Phase 2 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | February 12, 2021 | February 2025 |
| NCT04150640 | Recruiting | Phase 2 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | July 13, 2020 | December 2026 |
| NCT05839470 | Recruiting | Phase 2 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | November 19, 2023 | March 1, 2025 |
| NCT04257461 | Recruiting | Phase 3 | A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma | February 20, 2020 | December 31, 2025 |
| NCT04248452 | Recruiting | Phase 3 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | May 26, 2020 | March 31, 2028 |
| NCT04245865 | Recruiting | Phase 2 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | June 26, 2020 | October 2024 |
| NCT05329766 | Recruiting | Phase 2 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | June 10, 2022 | June 2027 |
| NCT05555888 | Recruiting | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） | December 12, 2022 | November 1, 2025 |
| NCT05849480 | Recruiting | Phase 1/Phase 2 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | May 8, 2024 | June 1, 2042 |
| NCT05319639 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | February 16, 2023 | December 31, 2024 |
| NCT05859477 | Recruiting | Phase 2 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | June 5, 2022 | December 1, 2024 |
| NCT05863195 | Recruiting | Phase 3 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | October 19, 2023 | June 30, 2034 |
| NCT05867121 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | October 2, 2023 | December 30, 2025 |
| NCT05307198 | Recruiting | Phase 2 | Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC | May 11, 2022 | April 25, 2025 |
| NCT05872685 | Recruiting | Phase 2 | Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) | December 24, 2023 | April 30, 2029 |
| NCT04566380 | Recruiting | Phase 2 | ONO-4538 Phase II Rollover Study (ONO-4538-98) | September 10, 2020 | December 31, 2026 |
| NCT04539808 | Recruiting | Phase 2 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | May 27, 2021 | October 5, 2025 |
| NCT04518280 | Recruiting | Phase 2 | Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer | May 1, 2021 | December 31, 2025 |
| NCT04495296 | Recruiting | Phase 1/Phase 2 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | August 13, 2020 | November 1, 2024 |
| NCT05476796 | Recruiting | Phase 2 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | June 23, 2023 | January 2027 |
| NCT04615013 | Recruiting | Phase 1 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | November 23, 2020 | October 31, 2025 |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT06341595 | Recruiting | Phase 2 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | April 1, 2024 | December 31, 2026 |
| NCT05472259 | Recruiting | Phase 2 | A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | May 25, 2022 | December 31, 2027 |
| NCT04595929 | Recruiting | N/A | Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- | February 10, 2020 | January 10, 2029 |
| NCT05417386 | Recruiting | Phase 1 | FOLFIRINOX + NIS793 in Pancreatic Cancer | August 9, 2022 | May 1, 2025 |
| NCT05688215 | Suspended | Phase 1/Phase 2 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | March 7, 2023 | May 1, 2026 |
| NCT04607772 | Suspended | Phase 1/Phase 2 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | November 18, 2020 | December 2025 |
| NCT00627432 | Suspended | Phase 2 | Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | July 2004 | |
| NCT02121405 | Suspended | Phase 3 | Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM | October 2015 | February 2026 |
| NCT04894123 | Terminated | Phase 2 | Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients | February 7, 2022 | February 13, 2023 |
| NCT02076594 | Terminated | Phase 3 | Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer | January 2013 | December 31, 2018 |
| NCT02141295 | Terminated | Phase 2 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer | June 30, 2014 | February 1, 2017 |
| NCT02216149 | Terminated | Phase 2 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow | January 2015 | August 2018 |
| NCT02244489 | Terminated | Phase 1 | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | November 5, 2014 | April 5, 2017 |
| NCT00508872 | Terminated | Phase 2 | Folfox-B Study for Patients With Colorectal Liver Metastases | November 2005 | June 2009 |
| NCT02345460 | Terminated | Phase 2 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | September 2015 | March 2016 |
| NCT02359162 | Terminated | Phase 3 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | May 2015 | June 2017 |
| NCT02384850 | Terminated | Phase 1 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | March 2015 | March 9, 2017 |
| NCT02392377 | Terminated | Phase 2 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy | February 2015 | December 2015 |
| NCT00480987 | Terminated | Phase 1/Phase 2 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | July 2007 | August 2010 |
| NCT02533323 | Terminated | Phase 2 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | January 2012 | January 2017 |
| NCT00463840 | Terminated | Phase 1/Phase 2 | Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer | June 2004 | October 2015 |
| NCT02630043 | Terminated | Phase 1 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | December 2015 | July 2019 |
| NCT02720926 | Terminated | Phase 1 | Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | September 2011 | January 2012 |
| NCT02842580 | Terminated | Phase 2 | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | September 2016 | October 2020 |
| NCT02862535 | Terminated | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | September 20, 2016 | October 25, 2019 |
| NCT00448682 | Terminated | Phase 2 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery | June 2005 | March 2010 |
| NCT02951156 | Terminated | Phase 3 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | December 16, 2016 | December 2, 2019 |
| NCT02953509 | Terminated | Phase 1/Phase 2 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | November 21, 2016 | March 25, 2024 |
| NCT03009058 | Terminated | Phase 1/Phase 2 | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | May 24, 2017 | August 30, 2017 |
| NCT00430027 | Terminated | N/A | Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma | November 2006 | August 2008 |
| NCT03026803 | Terminated | Phase 2 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | November 2006 | October 2014 |
| NCT03050814 | Terminated | Phase 2 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | April 5, 2017 | August 25, 2021 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT00418093 | Terminated | Phase 2 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | September 2006 | October 2011 |
| NCT00403988 | Terminated | Phase 2 | Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma | June 2004 | December 2007 |
| NCT03294252 | Terminated | Phase 1/Phase 2 | Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers | May 24, 2017 | October 1, 2021 |
| NCT03300544 | Terminated | Phase 1 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | May 14, 2019 | March 22, 2022 |
| NCT03300609 | Terminated | Phase 3 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | February 27, 2018 | October 3, 2019 |
| NCT00356941 | Terminated | Phase 1 | Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC | April 2006 | May 2007 |
| NCT00354224 | Terminated | Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer | January 2005 | August 2008 |
| NCT03387098 | Terminated | Phase 1/Phase 2 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | December 28, 2017 | January 15, 2019 |
| NCT00351195 | Terminated | Phase 2 | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) | February 2006 | April 2007 |
| NCT00335959 | Terminated | Phase 2 | S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery | May 2006 | |
| NCT03427021 | Terminated | Early Phase 1 | A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity | February 1, 2017 | October 23, 2018 |
| NCT00321100 | Terminated | Phase 2 | Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab | April 12, 2006 | December 18, 2013 |
| NCT03488251 | Terminated | Phase 2 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | August 20, 2018 | March 12, 2021 |
| NCT00314353 | Terminated | Phase 2 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | March 2006 | June 2010 |
| NCT03500874 | Terminated | Phase 3 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | May 28, 2018 | August 31, 2021 |
| NCT00313612 | Terminated | Phase 2 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | January 2006 | December 2012 |
| NCT03515941 | Terminated | Early Phase 1 | Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers | June 22, 2018 | June 18, 2020 |
| NCT00307723 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | May 2006 | July 2009 |
| NCT00303628 | Terminated | Phase 3 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | May 11, 2006 | February 11, 2019 |
| NCT00296062 | Terminated | Phase 1 | Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer | March 2006 | May 2011 |
| NCT00276861 | Terminated | Phase 2 | Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer | September 2005 | May 2008 |
| NCT03645876 | Terminated | Phase 2 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | November 8, 2018 | April 18, 2019 |
| NCT03678428 | Terminated | Phase 3 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | December 31, 2021 | December 31, 2022 |
| NCT00268463 | Terminated | Phase 3 | Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer | January 2006 | June 2008 |
| NCT00268151 | Terminated | Phase 1 | Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer | February 2005 | |
| NCT00259363 | Terminated | Phase 1/Phase 2 | Oxaliplatin in Rectal Cancer | October 2002 | |
| NCT00256321 | Terminated | Phase 2 | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma | October 2004 | August 2007 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00256308 | Terminated | Phase 2 | Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer | February 2005 | October 2011 |
| NCT00256295 | Terminated | Phase 2 | Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer | April 2005 | October 2011 |
| NCT00256269 | Terminated | Phase 2 | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma | June 2005 | February 7, 2007 |
| NCT00227617 | Terminated | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | June 8, 2005 | February 2016 |
| NCT00226941 | Terminated | Phase 1/Phase 2 | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | June 2004 | February 2009 |
| NCT00216073 | Terminated | Phase 2 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | March 2004 | October 2006 |
| NCT00209703 | Terminated | Phase 2 | Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer | January 2005 | June 2007 |
| NCT00184028 | Terminated | Phase 2 | Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck | September 2004 | July 2010 |
| NCT04158349 | Terminated | Phase 1 | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer | March 22, 2021 | May 14, 2021 |
| NCT00129870 | Terminated | Phase 4 | CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer | February 2005 | December 2007 |
| NCT00591149 | Terminated | Phase 2 | Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | June 2007 | April 2012 |
| NCT00602329 | Terminated | Phase 2 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | February 2006 | October 2009 |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT00612677 | Terminated | Phase 2 | Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem | June 2007 | January 2008 |
| NCT00101075 | Terminated | Phase 2 | Title XELOX FOR SALIVARY GLAND CANCERS | October 2004 | March 2008 |
| NCT00093652 | Terminated | Phase 1/Phase 2 | Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer | May 2003 | |
| NCT00625183 | Terminated | Phase 2 | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma | March 2008 | December 2009 |
| NCT00087334 | Terminated | Phase 1/Phase 2 | Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer | January 2004 | |
| NCT00642603 | Terminated | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | May 2008 | March 2009 |
| NCT00642746 | Terminated | Phase 2 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | March 2008 | December 2011 |
| NCT00086983 | Terminated | Phase 1 | Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors | May 2004 | |
| NCT00674206 | Terminated | Phase 2 | A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer | October 2008 | October 2009 |
| NCT00077233 | Terminated | Phase 3 | FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | December 2003 | June 2010 |
| NCT00564720 | Terminated | Phase 2 | Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer | December 2006 | March 2011 |
| NCT00720512 | Terminated | Phase 3 | Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab | June 2008 | March 2014 |
| NCT00732745 | Terminated | Phase 1 | Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction | October 2008 | |
| NCT00755118 | Terminated | Phase 2 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | October 2008 | August 2012 |
| NCT00755534 | Terminated | Phase 2 | Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | November 2008 | November 2008 |
| NCT00766142 | Terminated | Phase 2 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer | May 1, 2007 | September 17, 2013 |
| NCT00782041 | Terminated | Phase 2 | Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer | January 2003 | |
| NCT00551759 | Terminated | Phase 2 | Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | October 2, 2008 | February 2014 |
| NCT00070265 | Terminated | Phase 2 | Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer | August 2003 | |
| NCT00070122 | Terminated | Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | April 2004 | |
| NCT00066625 | Terminated | Phase 1 | Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer | July 2003 | |
| NCT00955721 | Terminated | Phase 1/Phase 2 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | August 2009 | July 2014 |
| NCT00065117 | Terminated | Phase 2 | Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. | September 2003 | February 2004 |
| NCT00051688 | Terminated | Phase 2 | Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer | June 2003 | August 2004 |
| NCT04675983 | Terminated | Phase 3 | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | March 10, 2021 | February 12, 2023 |
| NCT00043004 | Terminated | Phase 2 | Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer | May 2002 | |
| NCT00541112 | Terminated | Phase 2 | Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | October 29, 2007 | January 29, 2010 |
| NCT01198548 | Terminated | Phase 2 | High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer | August 2010 | June 2012 |
| NCT01229111 | Terminated | Phase 2 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | October 2010 | March 2014 |
| NCT01233505 | Terminated | Phase 1 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | October 2010 | |
| NCT04933227 | Terminated | Phase 2 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | August 6, 2021 | November 17, 2023 |
| NCT00006121 | Terminated | Phase 2 | Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | May 2000 | |
| NCT01279681 | Terminated | Phase 3 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | January 2011 | November 1, 2014 |
| NCT01280643 | Terminated | N/A | Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | March 2010 | May 2014 |
| NCT01307956 | Terminated | Phase 2 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | February 28, 2011 | December 23, 2015 |
| NCT01320683 | Terminated | Phase 2 | Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer | March 2011 | December 2014 |
| NCT01370876 | Terminated | Phase 2 | Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer | September 2010 | May 2012 |
| NCT01372202 | Terminated | Phase 2 | CHFR Methylation Status Esophageal Cancer Study | June 2011 | October 1, 2014 |
| NCT00006015 | Terminated | Phase 2 | Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2000 | February 2003 |
| NCT01525069 | Terminated | Phase 1 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | April 3, 2012 | August 2, 2022 |
| NCT01531712 | Terminated | Phase 2 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable | February 10, 2011 | December 2012 |
| NCT00005856 | Terminated | Phase 1/Phase 2 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | December 2000 | |
| NCT01665274 | Terminated | Phase 2 | Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer | September 2013 | September 2022 |
| NCT01715363 | Terminated | Phase 2 | Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer | July 2012 | June 2014 |
| NCT01765582 | Terminated | Phase 2 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | January 23, 2013 | March 14, 2016 |
| NCT01769508 | Terminated | Phase 2 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer | February 2013 | February 2015 |
| NCT01858662 | Terminated | Phase 2 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | January 2014 | November 2015 |
| NCT00539617 | Terminated | Phase 2 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | October 5, 2007 | May 12, 2011 |
| NCT05546411 | Terminated | Phase 2 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | January 6, 2023 | October 13, 2023 |
| NCT01897454 | Terminated | Phase 2 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | January 27, 2012 | November 1, 2021 |
| NCT00537823 | Terminated | Phase 2 | Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | June 2007 | July 2011 |
| NCT01936974 | Terminated | Phase 2 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | September 2013 | August 2015 |
| NCT01955629 | Terminated | Phase 1/Phase 2 | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient | December 2013 | March 2015 |
| NCT02506842 | Unknown status | Phase 3 | Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection | June 2015 | June 2019 |
| NCT00003260 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | January 1998 | |
| NCT00274872 | Unknown status | Phase 2/Phase 3 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | January 2004 | |
| NCT03691454 | Unknown status | Phase 2/Phase 3 | Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. | June 28, 2018 | June 30, 2023 |
| NCT00075543 | Unknown status | Phase 1/Phase 2 | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | July 2003 | |
| NCT04072198 | Unknown status | Phase 2 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | September 26, 2019 | September 2022 |
| NCT00690300 | Unknown status | Phase 2 | Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | January 2008 | December 2010 |
| NCT04065282 | Unknown status | Phase 2 | The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. | August 6, 2019 | March 1, 2022 |
| NCT04337879 | Unknown status | Phase 1/Phase 2 | A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | July 20, 2020 | December 31, 2020 |
| NCT00238849 | Unknown status | Phase 2 | Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC. | ||
| NCT04340401 | Unknown status | Phase 2 | Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen | May 25, 2020 | April 2022 |
| NCT04008511 | Unknown status | Phase 1/Phase 2 | Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | July 2019 | March 2024 |
| NCT01716949 | Unknown status | Phase 1/Phase 2 | Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer | September 2012 | June 2023 |
| NCT02415699 | Unknown status | Phase 2/Phase 3 | DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer | August 2015 | July 2020 |
| NCT04003792 | Unknown status | Phase 2 | Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. | January 1, 2020 | January 2022 |
| NCT00004173 | Unknown status | Phase 1 | Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer | October 1999 | |
| NCT01729481 | Unknown status | Phase 2 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | July 2012 | December 2017 |
| NCT01732380 | Unknown status | Phase 2 | A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer | July 2012 | July 2013 |
| NCT00075452 | Unknown status | Phase 3 | Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma | November 2003 | |
| NCT03990103 | Unknown status | Phase 2 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | November 1, 2017 | April 30, 2022 |
| NCT04367025 | Unknown status | Phase 2 | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | May 2020 | May 2023 |
| NCT00072553 | Unknown status | Phase 2 | Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | September 2003 | |
| NCT03825328 | Unknown status | Phase 2 | A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC ) | January 30, 2019 | December 30, 2020 |
| NCT03817411 | Unknown status | Phase 2 | Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer | January 25, 2019 | January 25, 2021 |
| NCT03813784 | Unknown status | Phase 3 | A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer | March 7, 2019 | March 2023 |
| NCT04405206 | Unknown status | Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer | May 25, 2020 | December 30, 2023 | |
| NCT03795571 | Unknown status | Phase 1 | Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL | January 1, 2019 | December 31, 2019 |
| NCT03792269 | Unknown status | Phase 2 | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | January 1, 2016 | December 2020 |
| NCT03791905 | Unknown status | Phase 2 | PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma | January 15, 2019 | December 2023 |
| NCT00268411 | Unknown status | Phase 3 | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | September 2004 | |
| NCT03711240 | Unknown status | Phase 2 | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | January 8, 2019 | October 30, 2020 |
| NCT02403544 | Unknown status | Phase 1 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | September 2013 | December 2016 |
| NCT00884767 | Unknown status | Phase 2 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | September 2007 | |
| NCT02350686 | Unknown status | Phase 2 | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | May 14, 2015 | December 2020 |
| NCT00274885 | Unknown status | Phase 4 | Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | October 2005 | |
| NCT01798251 | Unknown status | Phase 2 | XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach | December 2012 | December 2015 |
| NCT01802645 | Unknown status | Phase 2 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | March 2013 | December 2020 |
| NCT03668418 | Unknown status | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | June 1, 2018 | May 31, 2022 | |
| NCT00275119 | Unknown status | Phase 2 | Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | November 2003 | |
| NCT03626922 | Unknown status | Phase 1 | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | May 15, 2019 | November 2022 |
| NCT00985556 | Unknown status | Phase 2 | Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer | January 2009 | |
| NCT03607643 | Unknown status | Phase 1/Phase 2 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | January 15, 2019 | December 15, 2020 |
| NCT03585673 | Unknown status | Phase 2 | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma | June 1, 2018 | March 30, 2021 |
| NCT01019863 | Unknown status | Phase 2 | Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma. | October 2008 | October 2011 |
| NCT03567629 | Unknown status | Phase 2 | Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer | May 29, 2018 | December 30, 2023 |
| NCT00058474 | Unknown status | Phase 3 | Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer | July 2004 | May 2016 |
| NCT03503604 | Unknown status | Phase 1 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | May 1, 2018 | March 1, 2019 |
| NCT01818973 | Unknown status | Phase 2 | Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer | March 2013 | March 2020 |
| NCT01064999 | Unknown status | Phase 2/Phase 3 | A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer | March 2010 | December 2014 |
| NCT03475615 | Unknown status | Phase 3 | A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites | March 16, 2018 | December 31, 2020 |
| NCT00544063 | Unknown status | Phase 1 | Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer | October 2006 | |
| NCT01092481 | Unknown status | Phase 3 | Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy | January 26, 2010 | December 2019 |
| NCT01097265 | Unknown status | Phase 2/Phase 3 | Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery | July 2010 | |
| NCT00323583 | Unknown status | Phase 2 | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | May 2006 | |
| NCT03448835 | Unknown status | Phase 2 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | March 7, 2018 | January 1, 2022 |
| NCT03448549 | Unknown status | Phase 3 | SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients | January 1, 2018 | January 1, 2024 |
| NCT01150045 | Unknown status | Phase 3 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | June 2010 | |
| NCT04802980 | Unknown status | Phase 1 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | April 28, 2020 | September 2023 |
| NCT03443492 | Unknown status | Phase 2 | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer | March 26, 2018 | December 31, 2020 |
| NCT01167725 | Unknown status | Phase 3 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | August 2010 | |
| NCT03368131 | Unknown status | Phase 2 | Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study | December 1, 2017 | December 31, 2020 |
| NCT03349866 | Unknown status | Phase 2 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction | November 30, 2017 | November 30, 2020 |
| NCT02339116 | Unknown status | Phase 3 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | February 26, 2015 | February 2021 |
| NCT00363831 | Unknown status | Phase 2 | Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma | July 2006 | |
| NCT03316326 | Unknown status | Phase 2 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | November 1, 2017 | December 31, 2021 |
| NCT01832948 | Unknown status | Phase 2 | Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer | January 2013 | January 2015 |
| NCT00008281 | Unknown status | Phase 3 | Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | October 2000 | |
| NCT00383695 | Unknown status | Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | September 2005 | |
| NCT00408551 | Unknown status | Phase 2 | Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver | November 2005 | |
| NCT03237507 | Unknown status | Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer | July 1, 2017 | June 1, 2020 | |
| NCT00006479 | Unknown status | Phase 3 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | September 2000 | |
| NCT00513266 | Unknown status | Phase 2 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | June 2007 | |
| NCT01227239 | Unknown status | Phase 1/Phase 2 | Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting | September 2010 | August 2016 |
| NCT00006468 | Unknown status | Phase 3 | Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | January 2000 | |
| NCT00496704 | Unknown status | Phase 1/Phase 2 | Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan | January 2007 | |
| NCT01843829 | Unknown status | Phase 2 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | October 2013 | May 2016 |
| NCT01959061 | Unknown status | Phase 4 | Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases | September 2013 | December 2017 |
| NCT00006117 | Unknown status | Phase 2 | Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | September 1999 | |
| NCT00510107 | Unknown status | Phase 2 | Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC | July 2007 | July 2009 |
| NCT02250209 | Unknown status | Phase 2 | T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy | July 2014 | December 2017 |
| NCT04963088 | Unknown status | Phase 1/Phase 2 | TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma | March 6, 2021 | March 20, 2024 |
| NCT01307592 | Unknown status | Phase 2 | Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma | February 2011 | |
| NCT00538005 | Unknown status | Phase 1/Phase 2 | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | May 2007 | |
| NCT01308086 | Unknown status | Phase 3 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | October 2010 | December 2017 |
| NCT00415298 | Unknown status | N/A | AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer | May 2006 | |
| NCT01963702 | Unknown status | Phase 2 | A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC | August 2012 | December 2014 |
| NCT03167112 | Unknown status | Phase 2 | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer | July 3, 2017 | May 2018 |
| NCT05018182 | Unknown status | Phase 2 | FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer | August 2, 2021 | August 2, 2022 |
| NCT02008422 | Unknown status | Phase 3 | Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer | August 2013 | August 2016 |
| NCT01899118 | Unknown status | Phase 2 | Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer | April 2013 | |
| NCT00425425 | Unknown status | Phase 1/Phase 2 | Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer | July 2006 | May 2015 |
| NCT03126071 | Unknown status | Phase 2 | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | February 15, 2017 | February 15, 2023 |
| NCT01384994 | Unknown status | Phase 2 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | August 2011 | August 2014 |
| NCT05056389 | Unknown status | Phase 1 | Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) | September 17, 2021 | June 30, 2023 |
| NCT03061058 | Unknown status | Phase 3 | Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC | April 1, 2013 | December 2019 |
| NCT03045770 | Unknown status | N/A | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA | February 10, 2017 | December 30, 2019 |
| NCT03013010 | Unknown status | Phase 3 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy | December 2016 | December 2023 |
| NCT03007446 | Unknown status | Phase 2 | The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer | November 2016 | November 2018 |
| NCT00006115 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | April 1999 | |
| NCT00438737 | Unknown status | Phase 2 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | January 2007 | |
| NCT03001726 | Unknown status | To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor. | January 2017 | December 2023 | |
| NCT01467921 | Unknown status | Phase 2 | Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma | December 2010 | |
| NCT01470443 | Unknown status | Phase 3 | Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma | December 28, 2011 | December 2020 |
| NCT01471132 | Unknown status | Phase 2 | Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis | September 2011 | September 2015 |
| NCT02949258 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer | January 2017 | January 2021 |
| NCT02918747 | Unknown status | Phase 2 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | September 2016 | December 2021 |
| NCT02177552 | Unknown status | Phase 2 | Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma | June 2014 | November 2019 |
| NCT01494363 | Unknown status | Phase 2 | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer | October 2011 | December 2013 |
| NCT01497041 | Unknown status | Phase 2 | A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment | February 2011 | December 2013 |
| NCT00452881 | Unknown status | Phase 2 | Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC | May 2006 | December 2014 |
| NCT02904031 | Unknown status | Phase 2 | Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients | July 2016 | October 2020 |
| NCT00453115 | Unknown status | Phase 2 | Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | January 2006 | May 2011 |
| NCT01511146 | Unknown status | Phase 2 | Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor | July 2011 | July 2016 |
| NCT01522989 | Unknown status | Phase 1 | PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies | December 2011 | December 2020 |
| NCT02021422 | Unknown status | Phase 1 | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | June 2013 | December 2017 |
| NCT01529164 | Unknown status | Phase 2 | Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer | October 2011 | September 2014 |
| NCT01921790 | Unknown status | Phase 2 | Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | August 2013 | August 2020 |
| NCT01542294 | Unknown status | Phase 1/Phase 2 | SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer | June 2011 | April 2017 |
| NCT02845986 | Unknown status | Phase 2 | Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer | September 1, 2016 | October 12, 2020 |
| NCT01558453 | Unknown status | Phase 2 | Oxaliplatin for Children With Solid Tumors | March 2011 | December 2013 |
| NCT02785146 | Unknown status | Phase 3 | Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer | June 2016 | June 2018 |
| NCT00004206 | Unknown status | Phase 2 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | September 1999 | |
| NCT01566942 | Unknown status | Phase 3 | FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer | June 2012 | June 2017 |
| NCT02767674 | Unknown status | Phase 3 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | May 2016 | December 2020 |
| NCT02745561 | Unknown status | Phase 2 | Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients. | January 2016 | December 2018 |
| NCT05291052 | Unknown status | Phase 2 | Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors | February 14, 2022 | March 30, 2024 |
| NCT02692248 | Unknown status | Phase 2 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation | April 7, 2016 | September 2020 |
| NCT02635971 | Unknown status | Phase 2 | Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer | December 2015 | December 2022 |
| NCT02623153 | Unknown status | Phase 2 | Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer | January 2016 | December 2019 |
| NCT02605265 | Unknown status | Phase 3 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 | October 2015 | December 2020 |
| NCT04202978 | Unknown status | Phase 1/Phase 2 | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | March 1, 2020 | November 1, 2021 |
| NCT01652196 | Unknown status | Phase 2 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | November 14, 2012 | December 31, 2019 |
| NCT00156975 | Unknown status | Phase 3 | Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases | November 2004 | |
| NCT02515734 | Unknown status | Phase 2 | A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | August 2015 | June 2020 |
| NCT00471484 | Unknown status | Phase 2 | Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | March 2007 | |
| NCT04097444 | Unknown status | Phase 2 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | October 11, 2019 | August 31, 2022 |
| NCT00182715 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | March 2005 | |
| NCT00274859 | Unknown status | Phase 2 | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer | August 2005 | |
| NCT02504229 | Unknown status | Phase 2 | DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment | November 2014 | |
| NCT01679327 | Unknown status | Phase 2 | Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | March 2012 | September 2014 |
| NCT00647530 | Unknown status | Phase 2/Phase 3 | Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | May 15, 2008 | December 31, 2019 |
| NCT04281576 | Unknown status | N/A | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | December 19, 2019 | September 2021 |
| NCT01679340 | Unknown status | Phase 2 | A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery | April 2011 | June 2018 |
| NCT02426450 | Unknown status | Phase 2 | RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC | April 2015 | April 2017 |
| NCT00482222 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | February 2007 | |
| NCT02085655 | Unknown status | Phase 3 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | April 25, 2013 | December 31, 2022 |
| NCT02046538 | Withdrawn | Phase 2 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | February 2014 | February 2018 |
| NCT00070434 | Withdrawn | Phase 2 | S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | August 2004 | |
| NCT02575508 | Withdrawn | Phase 1/Phase 2 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | ||
| NCT01270438 | Withdrawn | Phase 2 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | December 2010 | August 2013 |
| NCT01473303 | Withdrawn | Phase 1/Phase 2 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | August 2012 | |
| NCT02856867 | Withdrawn | Phase 2 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) | December 2016 | |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT03991104 | Withdrawn | Phase 1/Phase 2 | SOX-based CRT for Esophageal Cancer. | May 1, 2019 | December 31, 2023 |
| NCT01302613 | Withdrawn | Phase 1/Phase 2 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | March 2011 | November 2012 |
| NCT02413853 | Withdrawn | Phase 2 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | November 2015 | November 2018 |
| NCT03307941 | Withdrawn | Phase 1/Phase 2 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA | July 20, 2017 | December 11, 2017 |
| NCT00571740 | Withdrawn | Phase 2 | Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | ||
| NCT04859582 | Withdrawn | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | November 8, 2018 | November 29, 2024 |
| NCT02105350 | Withdrawn | Phase 1 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | June 2015 | June 2015 |
| NCT02345746 | Withdrawn | Phase 2 | Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis | December 2012 | December 2013 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT02129322 | Withdrawn | Phase 2 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | July 2015 | December 2019 |
| NCT03169790 | Withdrawn | Phase 1/Phase 2 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | December 2017 | March 2019 |
| NCT00728000 | Withdrawn | Phase 2 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | August 2008 | August 2010 |
| NCT03222089 | Withdrawn | Phase 2 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | July 20, 2017 | July 20, 2020 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT02585479 | Withdrawn | Phase 2/Phase 3 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | October 2015 | October 2017 |
| NCT04430985 | Withdrawn | Phase 2 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | September 30, 2020 | September 6, 2021 |
| NCT00408772 | Withdrawn | Phase 2 | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer | June 2007 | April 2008 |
| NCT02344810 | Withdrawn | Phase 1/Phase 2 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | March 6, 2015 | |
| NCT00118105 | Withdrawn | Phase 2 | S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer | November 2006 | April 2007 |
| NCT02296671 | Withdrawn | Phase 2 | Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers | February 2015 | February 2022 |
| NCT04796454 | Withdrawn | Phase 2 | Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | May 2022 | August 2026 |